Neuroblastoma is a cancer that shows a strange behavior: sometimes it regresses spontaneously, whereas other times it becomes malignant. A team from Nagoya University in Japan identified a previously unknown “uncommitted" neuroblastoma cell state and found that mice presumed to have undergone spontaneous regression exhibited a higher frequency of these uncommitted cells. Gene signatures of the uncommitted cell state were strongly associated with favorable prognosis in human neuroblastoma patients suggesting that understanding these cells could help treat this devastating disease.

City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) discovered a new and potentially revolutionary way to treat glioblastoma (GBM), the most aggressive type of brain cancer with no curative treatment options. An innovative study – led by Paul B. Fisher, MPh, Ph.D., FNAI, and Swadesh K. Das, Ph.D., and recently published in the Journal for ImmunoTherapy of Cancer – created a novel molecule that demonstrated the capability to introduce a combination of treatment outcomes – direct toxicity and immunotoxicity – to kill the tumor while exploiting immunotherapy to potentially prevent the recurrence of GBM via a “Fusion Superkine” (FSK), containing dual acting therapeutic cytokines in a single molecule.

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within tumours, opening doors for more targeted therapies for patients.

Two Purdue University researchers have received $50,000 apiece to develop their innovations in the fields of cancer treatments and freshwater management. The funding comes from the Trask Innovation Fund, managed by Purdue Innovates Incubator. The fund supports Purdue researchers through the “valley of death," the time to move an innovation from laboratory creation to marketplace product.

BUFFALO, NY – June 24, 2025 – A new precision oncology paper was published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.”